Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Localized Prostate Cancer
Advertisement
Latest News
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Research sheds light on the patient-reported outcomes from a 3-year focal therapy program for localized PCa using HIFU.
Hemi-gland cryoablation and HIFU provided acceptable and eminent functional outcomes in patients over a 5-year follow-up.
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Advertisement
Advertisement
Trending
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.